In this issue:

Valo Therapeutics Acquires Technology from Helsinki University

Gerresheimer Announces Pre-Fillable Syringe Product Line Expansion

EMA Recommends New Measures to Avoid Potentially Fatal Dosing Errors with Methotrexate

Top Stories

FDA Expands Scope of API Impurity Investigation

While downgrading the impact of nitrosamine impurities on patients, FDA vows to step up investigations for other drug types.
/ read more /

Drug Pricing and Politics

The multitude of health reform measures emerging on Capitol Hill has accelerated lobbying action across the board, along with campaign donations to candidates from all sides.
/ read more /

Industry News

EC Approves Tecentriq Combination Therapy for Metastatic Triple-Negative Breast Cancer

Roche revealed that the European Commission has approved the combination of Tecentriq (atezolizumab) with Abraxane for the treatment of adult patients with PD-L1-positive, metastatic triple-negative breast cancer.
/ read more /

New Trial Results Demonstrate Potential of Entresto in Reversing HFrEF damage

Novartis revealed results from two new clinical trials indicating that Entresto (sacubitril/valsartan) significantly improves measures of cardiac structure and function in heart failure with reduced ejection fraction.
/ read more /

Supplier News

Valo Therapeutics Acquires Technology from Helsinki University

Valo Therapeutics has acquired a technology from Helsinki University that is expected to broaden its approach and expand the capability of its cancer vaccines platform, PeptiCRAd.
/ read more /

Real-World Data Demonstrates Efficacy of OAC in Patients with NVAF

Findings from a real-world data analysis have been released from the Bristol-Myers Squibb-Pfizer Alliance, demonstrating that Eliquis is associated with lower rate of major bleeding compared with vitamin K antagonist, dabigatran or rivaroxaban.
/ read more /

Bio/Pharma News

Gerresheimer Announces Pre-Fillable Syringe Product Line Expansion

Gerresheimer has announced it will be expanding its ClearJect product line of pre-fillable syringes with a new 2.25-mL cyclic olefin polymer (COP) staked in needle (SIN) syringe.
/ read more /

Alvotech, Prestige Biopharma Form New
Manufacturing Partnership

Alvotech and Prestige Biopharma, have announced the formation of a new contract manufacturing partnership for the commercial production of a biosimilar.
/ read more /